Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Insider transactions by Thomas Malley, a director of Kiniksa Pharmaceuticals International, plc (KNSA) are reported for August 12–14, 2025. The Form 4 shows multiple option exercises and open-market sales. Mr. Malley exercised stock options at strike prices ranging from $1.86 to $15.47, converting options into Class A ordinary shares. The filing reports open-market sales totaling 207,898 shares sold across three days at weighted-average sale prices in the low $30s (individual weighted averages reported at $32.4, $33.32 and $33.09). After these transactions, Mr. Malley directly beneficially owned 12,546 Class A shares and indirectly beneficially owned 71,967 shares through Mossrock Capital, LLC. The filing notes all reported options are fully vested and exercisable and includes broker execution price ranges for the sales.
Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 notifies proposed sales of 78,233 Class A ordinary shares through Charles Schwab & Co., with an aggregate market value of $2,588,711.00 and an approximate sale date of 08/14/2025 on NASDAQ. The filing states these shares were acquired the same day by employee stock option exercise and disposed via a broker cashless exercise. The filer previously sold 49,407 shares on 08/12/2025 for $1,600,641.00 and 50,129 shares on 08/13/2025 for $1,670,468.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 144 proposing the sale of 50,129 Class A ordinary shares. The filing shows the shares were acquired and are to be sold on 08/13/2025 via an employee stock option exercise with payment described as Broker Payment for Cashless Exercise. The broker listed is Charles Schwab & Co., Inc. and the aggregate market value is $1,670,468.00. The filing reports 43,472,928 shares outstanding, so the offered block equals about 0.12% of outstanding shares. The document also discloses a sale by Thomas Malley of 49,407 shares on 08/12/2025 for $1,600,641.00. Several identifying fields (CIK/CCC and filer contact/name fields) are not populated in the provided content.
Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 144 notifying a proposed sale of 49,407 Class A ordinary shares on 08/12/2025, with an aggregate market value of $1,600,641.00. The shares represent part of the issuer's 43,472,928 outstanding shares and are to be sold on NASDAQ through Charles Schwab & Co., Inc.. The securities were acquired the same day via an employee stock option exercise and settled by a broker payment for cashless exercise. The filer reported "Nothing to Report" for sales in the past three months and included the standard representation that the seller is not aware of undisclosed material adverse information.
John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals (KNSA), exercised 29,325 share options at an exercise price of $3.80 and sold 29,325 Class A Ordinary Shares at a weighted average price of $32.55 under a Rule 10b5-1 trading plan. The filing states the option is fully vested and exercisable and reports post-transaction beneficial ownership figures of 86,728 and 57,403 Class A shares, plus 36,542 derivative securities. The sale was executed through a broker-dealer in multiple trades and the filer offers to provide trade-level price details on request.
Report: Form 4 filed for Ragosa Mark (address: 23 Old Bond Street, London) reporting transactions in Kiniksa Pharmaceuticals International, plc (KNSA). The reporting person is identified as a Director and Chief Financial Officer. Earliest transaction date: 08/04/2025. Form signed by Madelyn Zeylikman, Attorney-in-Fact, dated 08/06/2025.
Transactions: Table I shows two Class A Ordinary Share transactions on 08/04/2025 involving 18,889 shares at prices of $22.89 and $32.89, with reported post-transaction beneficial ownerships of 45,898 and 27,009. Table II reports a Share Option with exercise/conversion price $22.89 covering 18,889 underlying Class A shares, expiration 03/15/2031, and 2,036 derivative securities reported beneficially owned following the transaction. The filing states the transactions were effected pursuant to a 10b5-1 plan executed Sept 3, 2024 and discloses the option vesting schedule (vesting commencement 03/16/2021; 25% on first anniversary; monthly vesting over 36 months).